N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review.

The two expressed genes coding for N-acetyltransferase (NAT) activity, NAT1 and NAT2, are located on chromosome 8 at 8p21.3-23.1 and are polymorphic. Both enzymes are capable of N-acetylation, O-acetylation, and N,O-acetylation and are implicated in the activation and detoxification of known carcinogens. Single base-pair substitutions in NAT2 tend to occur in combination with other substitutions within the gene. As yet, less work has been done to characterize NAT1 allelic variants. Various methods for the detection of the reported polymorphisms exist. It is important to select a method that is appropriate to the population being studied. The functional significance of many NAT allelic variants has not been determined. Geographic and ethnic variation in the frequency of NAT2 genotypes associated with fast or intermediate acetylation has been observed. Insufficient data for NAT1 genotypes are available to reveal a clear geographic pattern. No consistent association has been found between acetylator phenotype or genotype and colorectal cancer. The lack of consistency can in part be accounted for by methodological factors, including limited statistical power. Possible interactions between the NAT genes and either environmental exposures or other polymorphic genes encoding xenobiotic metabolizing enzymes have been investigated in only a minority of these studies, and these studies have lacked statistical power to detect interactions.

[1]  F. Kadlubar,et al.  Role of aromatic amine acetyltransferase in human colorectal cancer. , 1986, Archives of surgery.

[2]  D. S. St. John,et al.  Cancer Risk in Relatives of Patients with Common Colorectal Cancer , 1993, Annals of Internal Medicine.

[3]  M. Díaz‐Rubio,et al.  Acetylator polymorphism in human colorectal carcinoma. , 1991, Cancer research.

[4]  R. Bayoumi,et al.  Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. , 1997, Pharmacogenetics.

[5]  S. Francis,et al.  GENETIC POLYMORPHISM OF CONJUGATING ENZYMES AND CANCER RISK : GSTM1, GSTT1, NAT1 and NAT2 , 1998 .

[6]  C. Smith,et al.  Genetic polymorphisms in xenobiotic metabolism. , 1994, European journal of cancer.

[7]  W C Willett,et al.  A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. , 1998, Cancer research.

[8]  J. Bruner,et al.  Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  F. Jiménez-Jiménez,et al.  Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease , 1998, Neurology.

[10]  B. Lin,et al.  Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. , 1994, Pharmacogenetics.

[11]  R. Bayoumi,et al.  A new mutation C759T in the polymorphic N-acetyltransferase (NAT2) gene. , 1997, Pharmacogenetics.

[12]  M. Leppert,et al.  NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  N. Probst-Hensch,et al.  Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. , 1998, Pharmacogenetics.

[14]  W. Haenszel,et al.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.

[15]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[16]  Jack A. Taylor,et al.  Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. , 1993, Carcinogenesis.

[17]  J. Benítez,et al.  Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. , 1995, Oncology.

[18]  P B Farmer,et al.  Coke oven workers study: the effect of exposure and GSTM1 and NAT2 genotypes on DNA adduct levels in white blood cells and lymphocytes as determined by 32P-postlabelling. , 1998, Mutation research.

[19]  T. Louis,et al.  Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  J. Freudenheim,et al.  Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. , 1996, JAMA.

[21]  K. Shibuta,et al.  Molecular genotyping for N‐acetylation polymorphism in Japanese patients with colorectal cancer , 1994, Cancer.

[22]  T. Deguchi,et al.  Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. , 1990, The Journal of biological chemistry.

[23]  P. E. Hanna.  Metabolic Activation and Detoxification of Arylamines , 1996, Current Medicinal Chemistry.

[24]  P. Knekt,et al.  Smoking and risk of colorectal cancer. , 1998, British Journal of Cancer.

[25]  M. Abe,et al.  N-acetylation polymorphism in Japanese patients with sarcoidosis. , 1997, Pharmacogenetics.

[26]  E. Zielińska,et al.  Arylamine N‐acetyltransferase (NAT2) gene mutations in children with allergic diseases , 1997, Clinical pharmacology and therapeutics.

[27]  E. Taioli,et al.  Functional significance of different human CYP1A1 genotypes. , 1994, Carcinogenesis.

[28]  F. Kadlubar,et al.  Aromatic amine acetyltransferase as a marker for colorectal cancer: Environmental and demographic associations , 1990, International journal of cancer.

[29]  Henry J. Lin,et al.  ACCELERATED PAPER: Lack of association between the polyadenylation polymorphism in the NATl (acetyltransferase 1) gene and colorectal adenomas , 1996 .

[30]  J. Potter,et al.  Determination of human NAT2 acetylator genotype by oligonucleotide ligation assay. , 1997, BioTechniques.

[31]  I. Kalina,et al.  Cytogenetic monitoring in coke oven workers. , 1998, Mutation research.

[32]  C. Smith,et al.  N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions , 1997, Gut.

[33]  R. Glashan,et al.  ROLE OF N-ACETYLTRANSFERASE PHENOTYPES IN BLADDER CARCINOGENESIS: A PHARMACOGENETIC EPIDEMIOLOGICAL APPROACH TO BLADDER CANCER , 1982, The Lancet.

[34]  D. Grant,et al.  Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. , 1996, Pharmacogenetics.

[35]  N. van Zandwijk,et al.  The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  M. Lechner,et al.  Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. , 1998, Carcinogenesis.

[37]  P. Boyle,et al.  Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk , 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[38]  L. Celotti,et al.  Urinary mutagenicity on TA98 and YG1024 Salmonella typhimurium strains after a hamburger meal: influence of GSTM1 and NAT2 genotypes. , 1998, Mutagenesis.

[39]  Y. Tanigawara,et al.  Genotyping of N‐acetylation polymorphism and correlation with procainamide metabolism , 1997, Clinical pharmacology and therapeutics.

[40]  A. McMichael,et al.  Diet, acetylator phenotype, and risk of colorectal neoplasia , 1996, The Lancet.

[41]  A. Daly,et al.  Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. , 1997, Carcinogenesis.

[42]  P. Philip,et al.  Acetylator status and its relationship to breast cancer and other diseases of the breast. , 1987, European journal of cancer & clinical oncology.

[43]  M A Butler,et al.  Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[45]  D. Grant,et al.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. , 1990, DNA and cell biology.

[46]  E. Schnakenberg,et al.  Genotyping of the polymorphic N‐acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients , 1998, Clinical genetics.

[47]  C. Marsden,et al.  Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease , 1997, The Lancet.

[48]  U. Meyer,et al.  Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. , 1996, Pharmacogenetics.

[49]  C. Jara,et al.  Hepatic acetylator polymorphism in breast cancer patients. , 1987, Oncology.

[50]  E. Lee,et al.  Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. , 1998, Pharmacogenetics.

[51]  J. Benítez,et al.  Lung cancer and mutations at the polymorphic NAT2 gene locus. , 1995, Pharmacogenetics.

[52]  T. Deguchi,et al.  Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. , 1991, Biochemical and biophysical research communications.

[53]  A. Llerena,et al.  Influence of genetic admixture on polymorphisms of drug‐metabolizing enzymes: Analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population , 1998, Clinical pharmacology and therapeutics.

[54]  J. Little,et al.  The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia. , 1996, Critical reviews in oncogenesis.

[55]  P. S. Nielsen,et al.  Environmental air pollution and DNA adducts in Copenhagen bus drivers--effect of GSTM1 and NAT2 genotypes on adduct levels. , 1996, Carcinogenesis.

[56]  T. Nomiyama,et al.  Evidence on N-acetyltransferase allele-associated metabolism of hydrazine in Japanese workers. , 1998, Journal of occupational and environmental medicine.

[57]  K. Wulff,et al.  Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression: 1. Genotype and N-acetylation in vivo. , 1997, Pharmacogenetics.

[58]  Y. Bechtel,et al.  Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes. , 1998, Pharmacogenetics.

[59]  L Nyström,et al.  Smoking and colorectal cancer: a 20-year follow-up study of Swedish construction workers. , 1996, Journal of the National Cancer Institute.

[60]  R. Hayes,et al.  Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[61]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[62]  T. Rustan,et al.  Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. , 1995, Cancer research.

[63]  I. Roots,et al.  Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. , 1997, Pharmacogenetics.

[64]  P. Dayer,et al.  N-acetyltranferase NAT1 and NAT2 genotypes and lung cancer risk , 1998 .

[65]  J. Brockmöller,et al.  NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. , 1996, Pharmacogenetics.

[66]  M. Pavlova,et al.  Acetylator phenotype in patients with breast cancer. , 1978, Oncology.

[67]  J. Brockmöller,et al.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. , 1995, American journal of human genetics.

[68]  M. Lemos,et al.  N-acetyltransferase genotypes in the Portuguese population. , 1998, Pharmacogenetics.

[69]  M. A. García,et al.  CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. , 1997, Age and ageing.

[70]  O. Ilhan,et al.  Polymorphic N‐acetylation capacity in breast cancer patients , 1990, International journal of cancer.

[71]  M. Longnecker,et al.  Acetylation polymorphism and prevalence of colorectal adenomas. , 1995, Cancer research.

[72]  D. Grant,et al.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Freudenheim,et al.  Risk of recurrent spontaneous abortion, cigarette smoking, and genetic polymorphisms in NAT2 and GSTM1. , 1998, Epidemiology.

[74]  D. Bell,et al.  A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. , 1998, Carcinogenesis.

[75]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[76]  E. Lee,et al.  Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. , 1995, Pharmacogenetics.

[77]  G. Fakis,et al.  Expression of arylamine N-acetyltransferase in human intestine , 1998, Gut.

[78]  B. Lin,et al.  Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. , 1993, American journal of human genetics.

[79]  W. Willett,et al.  A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. , 1994, Journal of the National Cancer Institute.

[80]  J. Geier,et al.  Genotype and phenotype of N‐acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy , 1998, Contact Dermatitis.

[81]  D. Hein,et al.  Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients. , 1991, Cancer research.

[82]  J. Brockmöller,et al.  Determination and allelic allocation of seven nucleotide transitions within the arylamine N‐acetyltransferase gene in the Polish population , 1996, Clinical pharmacology and therapeutics.

[83]  Gunnar Steineck,et al.  Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study , 1999, The Lancet.

[84]  R. Millikan,et al.  Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[85]  G A Colditz,et al.  A prospective study of family history and the risk of colorectal cancer. , 1994, The New England journal of medicine.

[86]  P. V. van Helden,et al.  Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. , 1997, American journal of respiratory and critical care medicine.

[87]  F. Schächter,et al.  Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci , 1998, Human Genetics.

[88]  D. Bell,et al.  Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. , 1995, Cancer research.

[89]  M. Leppert,et al.  Meat consumption, genetic susceptibility, and colon cancer risk: a United States multicenter case-control study. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[90]  R. Sinha,et al.  Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. , 1994, Cancer research.

[91]  T. Mitsudomi,et al.  N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. , 1997, Anticancer research.

[92]  K. Hemminki,et al.  Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[93]  L. Hagmar,et al.  MDA in plasma as a biomarker of exposure to pyrolysed MDI-based polyurethane: correlations with estimated cumulative dose and genotype for N-acetylation , 1996, International archives of occupational and environmental health.

[94]  C. Boland,et al.  Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. , 1995, Journal of the National Cancer Institute.

[95]  P. Routledge,et al.  Drug acetylation in breast cancer. , 1989, British Journal of Cancer.

[96]  J. Manson,et al.  A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. , 1997, Carcinogenesis.

[97]  Y. Oda,et al.  Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. , 1994, Carcinogenesis.

[98]  A. Risch,et al.  Chromosomal localization of human genes for arylamine N-acetyltransferase. , 1994, The Biochemical journal.

[99]  D. Grant,et al.  Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. , 1997, The Biochemical journal.

[100]  D. Grant,et al.  Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. , 1998, Pharmacogenetics.

[101]  W. Weber,et al.  Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. , 1993, Pharmacogenetics.

[102]  A. Risch,et al.  Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. , 1996, Pharmacology & toxicology.

[103]  J. Prados,et al.  Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. , 1998, British Journal of Cancer.

[104]  A. Wilcox,et al.  Xenobiotic metabolism genes and the risk of recurrent spontaneous abortion. , 1996, Epidemiology.

[105]  J. Benítez,et al.  Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. , 1996, Pharmacogenetics.

[106]  Y. Doki,et al.  Association between genetic polymorphisms of glutathione S‐transferase P1 and N‐acetyltransferase 2 and susceptibility to squamous‐cell carcinoma of the esophagus , 1998, International journal of cancer.

[107]  R. Hayes,et al.  The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Brockmöller,et al.  Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. , 1996, Cancer research.

[109]  C. Smith,et al.  N-acetyl transferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients. , 1998, British Journal of Cancer.

[110]  J. Mclaughlin,et al.  Increased risk of colorectal cancer among smokers: Results of a 26‐year follow‐up of us veterans and a review , 1994, International journal of cancer.

[111]  C. Smith,et al.  A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. , 1997, Journal of medical genetics.

[112]  J. Brockmöller,et al.  Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. , 1996, Cancer research.

[113]  K. Ilett,et al.  Acetylation phenotype in colorectal carcinoma. , 1987, Cancer research.

[114]  D. Bell,et al.  Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. , 1995, Cancer research.

[115]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[116]  K. Ilett,et al.  Acetylation phenotype is not associated with breast cancer. , 1990, Cancer research.